ContractProduct Manufacturing & Supply Agreement • December 23rd, 2015 • Cancer Prevention Pharmaceuticals, Inc. • Pharmaceutical preparations • Quebec
Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission
PRODUCT MANUFACTURING & SUPPLY AGREEMENTProduct Manufacturing & Supply Agreement • September 4th, 2015 • Cancer Prevention Pharmaceuticals, Inc. • Pharmaceutical preparations
This Assignment, Assumption, and Second Amendment (“Amendment”) is effective as of February __, 2012 (“Effective Date”) by and between sanofi-aventis Canada Inc., with offices at 2150 St-Elzear Boulevard West, Laval, Quebec, Canada H7L4A8 (“Sanofi Canada”), sanofi-aventis U.S. LLC, with offices at 55 Corporate Drive, Bridgewater, NJ 08807 (“Sanofi US”), and Cancer Prevention Pharmaceuticals, LLC (CPP), having its principal place of business 1760 East River Road, Suite 250, Tucson, AZ 85718 (hereinafter “CPP” and together with Sanofi Canada and Sanofi US, the “Parties”).
FIRST AMENDMENT TO THE PRODUCT MANUFACTURING & SUPPLY AGREEMENTProduct Manufacturing & Supply Agreement • September 4th, 2015 • Cancer Prevention Pharmaceuticals, Inc. • Pharmaceutical preparations • Quebec
BETWEEN : SANOFI-AVENTIS CANADA INC., having its head office and principal place of business at 2150 St-Elzear Boulevard West, Laval, Quebec, Canada H7L 4A8 ,
